Tag: NASDAQ:LABT

SARASOTA, FL – Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) (the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that it has completed the redemption of all remaining outstanding shares of its Series C Convertible Preferred Stock (the “Series C Preferred Stock”) pursuant to a…